Pelthos Therapeutics Inc. Common Stock (PTHS)

About PTHS

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult an…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

92

Website

ir.pelthos.com/

Fundamentals

1-day range

$24.22$25.84

Market cap

$93.29M

P/E (trailing)

—

P/E (forward)

-4.35

EPS (trailing)

$-20.59

Dividend yield

—

Beta

3.03

Avg. volume

53.3K

Forecasts

7 analyst ratings

Pelthos Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• PTHS

  Pelthos Therapeutics Inc. Common Stock

  $24.46

  ▼ 2.16%
  Market cap $93.29MP/E —
  $18.19$37.5
• KLRS

  Kalaris Therapeutics Inc. Common Stock

  $4.03

  ▼ 1.71%
  Market cap $96.36MP/E —
  $3.03$11.88
• BDTX

  Black Diamond Therapeutics Inc. Common Stock

  $2.23

  ▼ 1.76%
  Market cap $99.42MP/E —
  $1.6$4.94
• CGTX

  Cognition Therapeutics Inc. Common Stock

  $1.03

  ▼ 3.30%
  Market cap $79.79MP/E —
  $0.5501$3.1
• ATRA

  Atara Biotherapeutics Inc. Common Stock

  $9.16

  ▼ 0.97%
  Market cap $77.04MP/E —
  $3.92$19.15
• ENGN

  enGene Therapeutics Inc. Common Stock

  $1.83

  ▼ 4.19%
  Market cap $118.57MP/E —
  $1.4$12.25
• GNTA

  Genenta Science S.p.A. American Depositary Shares

  $1

  ▼ 1.96%
  Market cap $67.99MP/E —
  $0.55$10

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64
  benzinga · 8/14/2026
• Oppenheimer Maintains Outperform on Pelthos Therapeutics, Lowers Price Target to $64
  Benzinga · 8/14/2026
• Pelthos Therapeutics Inc. (PTHS) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/13/2026
• Pelthos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
  Benzinga · 8/13/2026
• Pelthos Therapeutics Q2 EPS $(6.62) Misses $(3.05) Estimate, Sales $15.603M Beat $15.273M Estimate
  Benzinga · 8/13/2026

• Friedberg Ezra M · July 2, 2026 · Sale

  24 @ $27.33
• Friedberg Ezra M · July 2, 2026 · Sale

  534 @ $26.03
• Matthew Pauls · July 2, 2026 · Sale

  94 @ $27.36
• Matthew Pauls · July 2, 2026 · Sale

  692 @ $26
• Peter Greenleaf · July 2, 2026 · Sale

  85 @ $27.27
• Peter Greenleaf · July 2, 2026 · Sale

  712 @ $26
• Davis Todd C · June 11, 2026 · Buy

  503 @ $28.73
• Davis Todd C · June 11, 2026 · Buy

  35.4K @ $27.8
• Knuettel Francis II · May 22, 2026 · Disposition

  42.5K
• Knuettel Francis II · May 22, 2026 · Grant

  59.5K
• Knuettel Francis II · May 22, 2026 · Sale

  1.5K @ $26.84
• Knuettel Francis II · May 22, 2026 · Disposition

  13.9K
• Friedberg Ezra M · May 14, 2026 · Tax Withholding

  144 @ $27.01
• Malamut Richard · April 2, 2026 · Sale

  280 @ $21.36
• Malamut Richard · April 2, 2026 · Sale

  310 @ $20.51

Institutional Ownership

March 31, 2026

Total shares held

902.5K

Total value held

$18.96M

Institutional holders

16